NCT00819546View on ClinicalTrials.gov

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

RAD001

Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.

DRUG

PKC412

50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Richard Stone, MD

OTHER

NCT00819546 - RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | Biotech Hunter | Biotech Hunter